Protein A, G and L Resins - Global Strategic Business Report

The global market for Protein A, G and L Resins was valued at US$792.0 Million in 2025 and is projected to reach US$908.2 Million by 2032, growing at a CAGR of 2.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Protein A, G, And L Resins Market - Key Trends & Drivers Summarized

Why Are Protein A, G, and L Resins Gaining Strategic Importance in Biopharmaceutical Purification?

Protein A, G, and L resins are critical affinity chromatography media used in the downstream purification of monoclonal antibodies (mAbs), recombinant proteins, and immunoglobulins. Their high selectivity for specific immunoglobulin (Ig) domains makes them essential in ensuring product purity, yield, and efficiency in bioprocessing workflows. Protein A resins, derived from Staphylococcus aureus, have become the industry standard for capturing IgG antibodies due to their strong binding affinity for the Fc region. Protein G and Protein L resins complement this capability by enabling purification of antibody fragments and Ig subtypes that Protein A does not efficiently bind.

As the biopharmaceutical industry expands its focus beyond mAbs to include bispecific antibodies, antibody fragments, and fusion proteins, the need for versatile and subtype-specific resins has intensified. Protein G resins bind a broader range of IgG subclasses across various species, while Protein L resins uniquely target kappa light chains, enabling purification of Fab fragments, scFv, and other light-chain-containing constructs. The diversity of these affinity ligands allows manufacturers to fine-tune purification strategies across preclinical, clinical, and commercial-scale production pipelines-enhancing throughput, compliance, and scalability.

Which End-Use Segments and Bioprocessing Applications Are Driving Adoption of Affinity Resins?

The primary end-user segment for Protein A, G, and L resins is the biopharmaceutical manufacturing industry, particularly in monoclonal antibody production for therapeutic and diagnostic applications. During large-scale manufacturing, Protein A chromatography serves as the first capture step in downstream processing, ensuring removal of process-related impurities and concentration of the target antibody. This step is foundational for achieving regulatory-grade purity and lot consistency. With mAbs constituting over 60% of current biologic drug approvals, the demand for Protein A resins continues to surge in both originator and biosimilar pipelines.

Protein G and L resins are increasingly utilized in research laboratories, contract development and manufacturing organizations (CDMOs), and diagnostic reagent companies. In particular, Protein G is valuable for purifying polyclonal IgG from animal models used in preclinical studies. Protein L resins, which lack Fc-binding properties, are used for isolating antibody fragments from bacterial or mammalian expression systems-especially in next-generation antibody therapies like CAR-T, nanobodies, and ADCs. These resins are also important for immunoprecipitation, immunoassay development, and analytical protein quantification in quality control labs.

How Are Resin Technologies, Binding Capacities, and Reusability Advancing Market Offerings?

Innovations in resin matrix materials, ligand engineering, and elution conditions are enhancing the performance of affinity resins across parameters such as dynamic binding capacity (DBC), chemical stability, and cycle life. Protein A ligands are being genetically modified or chemically engineered to reduce leaching, lower non-specific binding, and improve alkaline stability-enabling reuse across multiple purification cycles without significant loss in functionality. Manufacturers like Cytiva (MabSelect), Repligen (Natrix), Purolite, and Tosoh Bioscience are offering next-generation Protein A resins with DBC exceeding 50 mg/mL and caustic resistance suitable for 100+ cycles.

Disposable column formats and membrane-based affinity chromatography platforms are also gaining traction, particularly in single-use bioprocessing. These solutions reduce cleaning validation burdens, minimize cross-contamination, and support continuous manufacturing models. Additionally, Protein G and L resins are available in multiple bead sizes and formats (agarose, polymethacrylate, synthetic polymers), allowing compatibility with high-pressure liquid chromatography (HPLC) and fast protein liquid chromatography (FPLC) systems. Some formulations now integrate multi-modal ligands to improve selectivity for antibody-drug conjugates and complex fusion proteins, reflecting the shift toward tailored purification workflows.

What Factors Are Driving the Growth of the Global Protein A, G, and L Resins Market?

The growth in the global Protein A, G, and L resins market is driven by the increasing number of antibody-based therapeutics, rising demand for biosimilars, and expansion of CDMO capacities worldwide. As mAbs, antibody fragments, and novel biologics dominate the drug development pipeline, downstream purification has emerged as a bottleneck-placing pressure on manufacturers to adopt high-efficiency resins with minimal leaching and high throughput. Protein A resins remain irreplaceable in most IgG purification protocols, while Protein G and L address growing needs in research and advanced therapy platforms.

Further, the rise in personalized medicine and cell & gene therapy is boosting small-batch and flexible manufacturing formats, which benefit from scalable, reusable, and single-use resin solutions. Continuous bioprocessing, facilitated by high-capacity resins, is gaining favor for its operational efficiency and reduced footprint. Increasing regulatory scrutiny around product purity and resin extractables is pushing vendors to develop more robust and chemically inert matrices, supported by detailed validation data and GMP compliance.

Major market participants include Cytiva (Danaher), Thermo Fisher Scientific, Merck KGaA, Repligen, Purolite (Ecolab), Tosoh Corporation, Bio-Rad, and Takara Bio. These companies are investing in resin innovation, ligand development, and expanded manufacturing footprints to serve growing biologics hubs in Asia-Pacific, North America, and Europe. With continued biopharma investment in antibody modalities and purification optimization, the Protein A, G, and L resins market is positioned for sustained, high-value growth.

Report Scope

The report analyzes the Protein A, G and L Resins market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (Protein G Resin, Protein L Resin, Protein A Resin); Application (Pharmaceuticals Application, Research Labs Application, Other Applications)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Protein G Resin segment, which is expected to reach US$509.9 Million by 2032 with a CAGR of a 2.2%. The Protein L Resin segment is also set to grow at 1.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $215.8 Million in 2025, and China, forecasted to grow at an impressive 3.5% CAGR to reach $169.6 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Protein A, G and L Resins Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein A, G and L Resins Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Protein A, G and L Resins Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abcam plc, Agarose Bead Technologies, Agilent Technologies, Inc., Avantor, Inc., Bio-Rad Laboratories, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Protein A, G and L Resins market report include:

• Abcam plc
• Agarose Bead Technologies
• Agilent Technologies, Inc.
• Avantor, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare (Cytiva)
• EMD Millipore (Merck KGaA)
• GenScript Biotech Corporation
• JSR Life Sciences Corporation
• Kaneka Corporation
• Novasep Holding SAS
• Pall Corporation (Danaher)
• PerkinElmer, Inc.
• Prometic Life Sciences Inc.
• Purolite Life Sciences (Ecolab)
• Repligen Corporation
• Sartorius Stedim Biotech S.A.
• Thermo Fisher Scientific Inc.
• Tosoh Bioscience LLC
• W. R. Grace & Co.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.